Compounds > terazosin

Page last updated: 2024-08-16

terazosin and labetalol

terazosin has been researched along with labetalol in 11 studies

Research

Studies (11)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (54.55)	29.6817
2010's	5 (45.45)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Campillo, NE; Guerra, A; Páez, JA	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Armstrong, SP; Ayoub, MA; Mustafa, S; Pfleger, KD; See, HB; Seeber, RM; Ventura, S; White, CW	1
Ong, CT; Sung, SF; Tong, SH; Wu, CS	1

Reviews

1 review(s) available for terazosin and labetalol

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

10 other study(ies) available for terazosin and labetalol

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Cheminformatic models to predict binding affinities to human serum albumin. Journal of medicinal chemistry, 2001, Dec-06, Volume: 44, Issue:25 Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids	2001
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Neural computational prediction of oral drug absorption based on CODES 2D descriptors. European journal of medicinal chemistry, 2010, Volume: 45, Issue:3 Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical	2010
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Identification and profiling of novel α1A-adrenoceptor-CXC chemokine receptor 2 heteromer. The Journal of biological chemistry, 2012, Apr-13, Volume: 287, Issue:16 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Allosteric Regulation; Animals; Arrestins; beta-Arrestins; Chemokines; CHO Cells; Cricetinae; HEK293 Cells; Humans; Inositol Phosphates; Labetalol; Male; Mice; Mice, Inbred C57BL; Norepinephrine; Prazosin; Prostate; Protein Structure, Quaternary; Receptors, Adrenergic, alpha-1; Receptors, G-Protein-Coupled; Receptors, Interleukin-8B	2012
Multiple cerebral infarctions related to famotidine-induced eosinophilia. Journal of neurology, 2012, Volume: 259, Issue:10 Topics: Acarbose; Adrenergic alpha-1 Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Calcium Channel Blockers; Cerebral Infarction; Diabetes Mellitus, Type 2; Diffusion Magnetic Resonance Imaging; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Famotidine; Humans; Hypertension; Hypoglycemic Agents; Labetalol; Male; Metformin; Middle Aged; Nifedipine; Peptic Ulcer; Prazosin; Sulfonylurea Compounds	2012